{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:54:08Z","timestamp":1782860048360,"version":"3.54.5"},"posted":{"date-parts":[[2024,9,22]]},"group-title":"Gastroenterology","reference-count":59,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,9,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>The inflammatory bowel diseases (IBD) known as Crohn\u2019s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract believed to arise because of an imbalance between the epithelial, immune and microbial systems. It has been shown that biological differences (genetic, epigenetic, microbial, environmental, etc.) exist between patients with IBD, with multiple risk factors been associated with disease susceptibility and IBD-related phenotypes (e.g. disease location). It is also known that there is heterogeneity in terms of response to therapy in patients with IBD, including to biological therapies that target very specific biological pathways (e.g. TNF-alpha signaling, IL-23R signaling, immune cell trafficking, etc.). It is hypothesized that the better the match between the biology targeted by these advanced therapies and the predominant disease-associated pathways at play in each patient will favor a beneficial response. The aim of this pilot study was to identify potential biological differences associated with differential treatment response to the anti \u03b14\u03b27 integrin therapy known as Vedolizumab. Our approach was to measure a broad range of analytes in the serum of patients prior to initiation of therapy and at the first clinical assessment visit, to identify potential markers of biological differences between patients at baseline and to see which biomarkers are most affected by treatment in responders. Our focus on early clinical response was to study the most proximal effects of therapy and to minimize confounders such as loss of response that occurs further distal to treatment initiation. Specifically, we performed targeted analyses of &gt;150 proteins and metabolites, and untargeted analyses of &gt;1100 lipid entities, in serum samples from 92 IBD patients (42 CD, 50 UC) immediately prior to initiation of therapy with vedolizumab (baseline samples) and at their first clinical assessment (14-week samples). We found lower levels of SDF-1a, but higher levels of PDGF-\u03b2\u03b2, lactate, lysine, phenylalanine, branched chain amino acids, alanine, short\/medium chain acylcarnitines, and triglycerides containing myristic acid in baseline serum samples of responders as compared to non-responders. We also observed an increase in serum levels of CXCL9 and citrate, as well as a decrease in IL-10, between baseline and week 14 samples. In addition, we observed that a group of metabolites and protein analytes was strongly associated with both treatment response and BMI status, although BMI status was not associated with treatment response.<\/jats:p>","DOI":"10.1101\/2024.09.19.24314034","type":"posted-content","created":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T15:20:12Z","timestamp":1727018412000},"source":"Crossref","is-referenced-by-count":3,"title":["A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-8326","authenticated-orcid":false,"given":"John D.","family":"Rioux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"Forest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Coderre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Daneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Robillard","family":"Frayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Thompson","family":"Legault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"iGenoMed","family":"Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-2795","authenticated-orcid":false,"given":"Sylvie","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramnik J.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Des","family":"Rosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2024092502000669000_2024.09.19.24314034v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27"},{"key":"2024092502000669000_2024.09.19.24314034v1.2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"issue":"12","key":"2024092502000669000_2024.09.19.24314034v1.3","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/ajg.2016.408","article-title":"Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn\u2019s Disease","volume":"111","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2024092502000669000_2024.09.19.24314034v1.4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/bmm.15.18","article-title":"Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis","volume":"9","year":"2015","journal-title":"Biomark Med"},{"issue":"41","key":"2024092502000669000_2024.09.19.24314034v1.5","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.3748\/wjg.v22.i41.9104","article-title":"Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy","volume":"22","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2024092502000669000_2024.09.19.24314034v1.6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fimmu.2017.00764","article-title":"Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles","volume":"8","year":"2017","journal-title":"Front Immunol"},{"key":"2024092502000669000_2024.09.19.24314034v1.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.105379"},{"key":"2024092502000669000_2024.09.19.24314034v1.8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178665"},{"key":"2024092502000669000_2024.09.19.24314034v1.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.10.041"},{"issue":"12","key":"2024092502000669000_2024.09.19.24314034v1.10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.it.2022.10.002","article-title":"Macrophage immunotherapy: overcoming impediments to realize promise","volume":"43","year":"2022","journal-title":"Trends Immunol"},{"key":"2024092502000669000_2024.09.19.24314034v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316023"},{"key":"2024092502000669000_2024.09.19.24314034v1.12","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000561"},{"issue":"8167","key":"2024092502000669000_2024.09.19.24314034v1.13","first-page":"514","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","year":"1980","journal-title":"Lancet"},{"key":"2024092502000669000_2024.09.19.24314034v1.14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.1.29"},{"key":"2024092502000669000_2024.09.19.24314034v1.15","doi-asserted-by":"crossref","unstructured":"Boucher G , Paradis A , Chabot-Roy G , Coderre L , Hillhouse EE , Bitton A , et al. Serum Analyte Profiles Associated With Crohn\u2019s Disease and Disease Location. Inflamm Bowel Dis. 2021.","DOI":"10.1016\/S0016-5085(21)01906-5"},{"issue":"7","key":"2024092502000669000_2024.09.19.24314034v1.16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/ibd\/izac281","article-title":"Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn\u2019s Disease","volume":"29","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2024092502000669000_2024.09.19.24314034v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxj037"},{"key":"2024092502000669000_2024.09.19.24314034v1.18","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.S087163"},{"key":"2024092502000669000_2024.09.19.24314034v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.09.054"},{"key":"2024092502000669000_2024.09.19.24314034v1.20","doi-asserted-by":"crossref","unstructured":"Ruiz M , Labarthe F , Fortier A , Bouchard B , Thompson Legault J , Bolduc V , et al. Circulating Acylcarnitine Profile in Human Heart Failure: A Surrogate of Fatty Acid Metabolic Dysregulation in Mitochondria and Beyond. Am J Physiol Heart Circ Physiol. 2017:ajpheart 00820 2016.","DOI":"10.1152\/ajpheart.00820.2016"},{"key":"2024092502000669000_2024.09.19.24314034v1.21","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JPROTEOME.8B00270"},{"key":"2024092502000669000_2024.09.19.24314034v1.22","doi-asserted-by":"crossref","unstructured":"Alkim C , Alkim H , Koksal AR , Boga S , Sen I . Angiogenesis in Inflammatory Bowel Disease. Int J Inflam. 2015;2015:970890.","DOI":"10.1155\/2015\/970890"},{"key":"2024092502000669000_2024.09.19.24314034v1.23","doi-asserted-by":"publisher","DOI":"10.1002\/path.4133"},{"key":"2024092502000669000_2024.09.19.24314034v1.24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00656.2013"},{"key":"2024092502000669000_2024.09.19.24314034v1.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"2024092502000669000_2024.09.19.24314034v1.26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.23.14899"},{"key":"2024092502000669000_2024.09.19.24314034v1.27","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i1.30"},{"key":"2024092502000669000_2024.09.19.24314034v1.28","doi-asserted-by":"crossref","unstructured":"Italiani P , Boraschi D . From Monocytes to M1\/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014;5:514.","DOI":"10.3389\/fimmu.2014.00514"},{"issue":"1","key":"2024092502000669000_2024.09.19.24314034v1.29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41385-021-00445-z","article-title":"Antibody secreting cells are critically dependent on integrin alpha4beta7\/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis","volume":"15","year":"2022","journal-title":"Mucosal Immunol"},{"key":"2024092502000669000_2024.09.19.24314034v1.30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316772"},{"key":"2024092502000669000_2024.09.19.24314034v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.11.006"},{"key":"2024092502000669000_2024.09.19.24314034v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2956"},{"key":"2024092502000669000_2024.09.19.24314034v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.06.010"},{"key":"2024092502000669000_2024.09.19.24314034v1.34","doi-asserted-by":"crossref","unstructured":"Li S , Gao D , Jiang Y. Function , Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites. 2019;9(2).","DOI":"10.3390\/metabo9020036"},{"key":"2024092502000669000_2024.09.19.24314034v1.35","doi-asserted-by":"crossref","unstructured":"Rosas-Ballina M , Guan XL , Schmidt A , Bumann D . Classical Activation of Macrophages Leads to Lipid Droplet Formation Without de novo Fatty Acid Synthesis. Front Immunol. 2020;11:131.","DOI":"10.3389\/fimmu.2020.00131"},{"issue":"10","key":"2024092502000669000_2024.09.19.24314034v1.36","first-page":"158981","article-title":"Lipid droplet: A functionally active organelle in monocyte to macrophage differentiation and its inflammatory properties","volume":"1866","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2024092502000669000_2024.09.19.24314034v1.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.16.5817"},{"key":"2024092502000669000_2024.09.19.24314034v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36332-3"},{"key":"2024092502000669000_2024.09.19.24314034v1.39","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.09-30"},{"issue":"6","key":"2024092502000669000_2024.09.19.24314034v1.40","first-page":"5009","article-title":"Imbalance of M1\/M2 macrophages is linked to severity level of knee osteoarthritis","volume":"16","year":"2018","journal-title":"Exp Ther Med"},{"issue":"1","key":"2024092502000669000_2024.09.19.24314034v1.41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12950-023-00360-z","article-title":"Advances in the study of macrophage polarization in inflammatory immune skin diseases","volume":"20","year":"2023","journal-title":"J Inflamm (Lond)"},{"key":"2024092502000669000_2024.09.19.24314034v1.42","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2014.909456"},{"issue":"94","key":"2024092502000669000_2024.09.19.24314034v1.43","doi-asserted-by":"crossref","first-page":"eadg7549","DOI":"10.1126\/sciimmunol.adg7549","article-title":"Gut-associated lymphoid tissue attrition associates with response to anti-alpha4beta7 therapy in ulcerative colitis","volume":"9","year":"2024","journal-title":"Sci Immunol"},{"issue":"9","key":"2024092502000669000_2024.09.19.24314034v1.44","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease","volume":"63","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2024092502000669000_2024.09.19.24314034v1.45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2018-000208"},{"issue":"5","key":"2024092502000669000_2024.09.19.24314034v1.46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2024092502000669000_2024.09.19.24314034v1.47","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jgh.15063","article-title":"Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice","volume":"35","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2024092502000669000_2024.09.19.24314034v1.48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12876-020-01253-8","article-title":"Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study","volume":"20","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"2024092502000669000_2024.09.19.24314034v1.49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ibd\/izaa251","article-title":"Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn\u2019s Disease","volume":"27","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024092502000669000_2024.09.19.24314034v1.50","doi-asserted-by":"crossref","first-page":"1756284820971214","DOI":"10.1177\/1756284820971214","article-title":"Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn\u2019s disease","volume":"13","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"2024092502000669000_2024.09.19.24314034v1.51","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.dld.2022.03.008","article-title":"Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab","volume":"54","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2024092502000669000_2024.09.19.24314034v1.52","first-page":"837294","article-title":"Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis","volume":"9","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024092502000669000_2024.09.19.24314034v1.53","doi-asserted-by":"crossref","unstructured":"Gabriels RY , Bourgonje AR , von Martels JZH , Blokzijl T , Weersma RK , Galinsky K , et al. Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. J Clin Med. 2022;11(14).","DOI":"10.3390\/jcm11144141"},{"issue":"12","key":"2024092502000669000_2024.09.19.24314034v1.54","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ibd\/izac151","article-title":"Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy","volume":"28","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024092502000669000_2024.09.19.24314034v1.55","doi-asserted-by":"crossref","unstructured":"Haglund S , Soderman J , Almer S . Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders. Int J Mol Sci. 2023;24(6).","DOI":"10.3390\/ijms24065820"},{"issue":"3","key":"2024092502000669000_2024.09.19.24314034v1.56","doi-asserted-by":"crossref","first-page":"e0145723","DOI":"10.1128\/spectrum.01457-23","article-title":"Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis","volume":"11","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"6","key":"2024092502000669000_2024.09.19.24314034v1.57","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ibd\/izad123","article-title":"Mucosal alpha4beta7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis","volume":"30","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2024092502000669000_2024.09.19.24314034v1.58","doi-asserted-by":"crossref","first-page":"21329","DOI":"10.1038\/s41598-023-48651-y","article-title":"PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab","volume":"13","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"2024092502000669000_2024.09.19.24314034v1.59","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn\u2019s Disease","volume":"157","year":"2019","journal-title":"Gastroenterology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.09.19.24314034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:12:36Z","timestamp":1768507956000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.09.19.24314034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2024.09.19.24314034","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1111\/imcb.70039","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,9,22]]},"subtype":"preprint"}}